Cargando…
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors
BACKGROUND: Ursolic acid is a promising anticancer agent. The current study aims to evaluate the single- and multiple-dose pharmacokinetics (PK) as well as the safety of ursolic acid nanoliposomes (UANL) in healthy volunteers and in patients with advanced solid tumors. METHODS: Twenty-four healthy v...
Autores principales: | Zhu, Zhongling, Qian, Zhengzi, Yan, Zhao, Zhao, Cuicui, Wang, Huaqing, Ying, Guoguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540956/ https://www.ncbi.nlm.nih.gov/pubmed/23319864 http://dx.doi.org/10.2147/IJN.S38271 |
Ejemplares similares
-
A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors
por: Qian, Zhengzi, et al.
Publicado: (2015) -
A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
por: Liu, Lian, et al.
Publicado: (2013) -
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
por: Chang, T. C., et al.
Publicado: (2015) -
A Modified Method for Determination of Lumefantrine in Human Plasma by HPLC-UV and Combination of Protein Precipitation and Solid-Phase Extraction: Application to a Pharmacokinetic Study
por: Huang, Liusheng, et al.
Publicado: (2010) -
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1)
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2022)